David A. Siegel Oramed Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $42.8 Billion
- Q1 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Oramed Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 213,000 shares of ORMP stock, worth $453,690. This represents 0.0% of its overall portfolio holdings.
Number of Shares
213,000
Previous 241,400
11.76%
Holding current value
$453,690
Previous $584,000
22.09%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ORMP
# of Institutions
62Shares Held
8.21MCall Options Held
11.2KPut Options Held
200-
Bml Capital Management, LLC Zionsville, IN3.02MShares$6.43 Million5.23% of portfolio
-
Murchinson Ltd. Toronto, A61.75MShares$3.73 Million0.46% of portfolio
-
Boothbay Fund Management, LLC New York, NY845KShares$1.8 Million0.06% of portfolio
-
Morgan Jess S & CO Inc366KShares$780,4342.07% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY252KShares$537,2370.61% of portfolio
About ORAMED PHARMACEUTICALS INC.
- Ticker ORMP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,827,100
- Market Cap $82.7M
- Description
- Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...